Whalesbook
Toh hua yeh hai ki, March 2026 ko khatam hui quarter mein net profit 74.5% se girkar ₹29.9 crore par aa gaya. Lekin funny baat yeh hai ki company ka revenue 23.6% badha aur ₹176.9 crore ho gaya! EBITDA toh 28.8% badh kar ₹32.8 crore ho gaya, aur margin bhi 17.8% se sudhar kar 18.6% ho gaya. Matlab operations toh theek chal rahe hain, phir bhi profit mein itni badi girawat? Tension toh banta hai.
Is news ke baad, company ka stock bhi 1.69% neeche band hua, ₹2,024.05 par. Market cap lagbhag ₹3,383.55 crore ke aas paas tha.
Revenue badhne ka main reason tha domestic formulations business, jo 18.2% badha. Indian Pharma Market (IPM) toh sirf 10.1% badha tha, toh RPG ne yahan aachi performance di. Aur jo API division band ho gaya tha, woh bhi 144.3% growth ke saath wapas aa gaya hai.
Waisey overall pharma sector mein bhi thodi mushkil chal rahi hai. US generics market mein problems hai, R&D aur marketing expenses badh rahe hain, jisse margins par pressure aa raha hai.
Ab sawal yeh hai ki profit itna kyun gira? Lagta hai koi bade expenses aa gaye hain ya kuch exceptional charges hain. January 2026 mein toh company ki quality rating bhi 'Good' se 'Average' ho gayi thi aur 'Sell' recommendation aa gayi thi. Kahan ja raha hai bhai ye? Kuch reports toh yeh bhi keh rahi hain ki pehle jo profit dikhta tha, woh 'other income' ki wajah se inflate ho raha tha. Matlab asal mein company ka operational profit shayad itna mazboot nahi hai.
Haan, ek acchi baat yeh hai ki company ne ₹24 per equity share ka final dividend recommend kiya hai. MD Ashok Nair ka kehna hai ki woh product pipeline strong karenge aur global reach badhayenge. Dekhte hain, kya yeh profit drop temporary hai ya kuch aur problem hai. Investors toh ab nazar rakhenge ki margins stable hote hain ya nahi.